Cypress Capital Group Invests $212,000 in United Therapeutics Co. (NASDAQ:UTHR)

Cypress Capital Group purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 591 shares of the biotechnology company’s stock, valued at approximately $212,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the second quarter valued at $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics during the second quarter valued at about $33,000. USA Financial Formulas bought a new position in shares of United Therapeutics during the third quarter valued at about $33,000. Finally, Capital Performance Advisors LLP bought a new position in shares of United Therapeutics during the third quarter valued at about $82,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. This represents a 67.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher Causey sold 510 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,796 shares of company stock worth $40,936,370. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Up 0.8 %

United Therapeutics stock opened at $367.36 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market capitalization of $16.40 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. The stock has a 50-day moving average price of $364.39 and a 200 day moving average price of $330.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the business earned $5.38 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Bank of America lowered their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.